Please ensure Javascript is enabled for purposes of website accessibility

Waiting for TASER

By Tim Beyers – Updated Apr 5, 2017 at 8:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The can't-lose technology takes another loss.

At least TASER (NASDAQ:TASR) management thinks shares of its company are cheap -- sort of.

During a second quarter in which the stun gun maker and two-time Rule Breakers recommendation reported its first per-share loss since 2006, management spent $12.5 million to repurchase 1.8 million shares.

Interestingly, they may have been buying some shares from longtime board member Bruce Culver. He's sold 136,000 shares since June 1. His last sale -- executed on June 30 -- was, according to this Form 4, to cover a margin call. Talk about weird. What was he betting on?

We can't know. What we do know is that it's tough to blame Culver for selling; TASER has underperformed recently. Look at yesterday's Q2 results: Revenue fell 18%. Operating income fell 85%, and that's after excluding the impact of a $5.2 million litigation charge.

Even our more than 11,000-strong Motley Fool CAPS community has mixed feelings about the stock:

Metric

TASER

CAPS stars (5 max)

***

Total ratings

1,099

Bullish ratings

1,014

Percent bulls

92.3%

Bearish ratings

85

Percent bears

7.7%

Bullish pitches

259

Bearish pitches

27

Data current as of July 25, 2008.

"Legal issues," wrote CAPS All-Star indiobravo in a bearish pitch made last month. "If deadly weapons are not so seriously taken by some law enforcers, these weapons will be party time."

Fair enough. But legal issues alone are no reason to avoid a stock. Baidu (NASDAQ:BIDU), Research In Motion (NASDAQ:RIMM), and PotashCorp (NYSE:POT) have all faced legal challenges over the past 12 months, according to Capital IQ.

To me, the TASER technology is inevitable -- a safer alternative to deadly weapons made by Smith & Wesson (NYSE:SWHC) and Sturm, Ruger (NYSE:RGR). What's troubling is the thing rocker Tom Petty called the hardest part: the waiting.

Get your clicks on related Foolishness:

Fool.com contributor Tim Beyers didn't own shares in any of the companies mentioned in this article at the time of publication. He hunts for tech's best as a contributor to Motley Fool Rule Breakers, which counts TASER and Baidu as holdings. Get a daily dose of his Foolish musings via this feed for your RSS reader. The Motley Fool's disclosure policy is a stunner.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axon Enterprise Stock Quote
Axon Enterprise
AXON
$113.46 (1.35%) $1.51
BlackBerry Stock Quote
BlackBerry
BB
$5.07 (-3.24%) $0.17
Nutrien Stock Quote
Nutrien
POT
Sturm, Ruger & Company, Inc. Stock Quote
Sturm, Ruger & Company, Inc.
RGR
$51.16 (0.69%) $0.35
Baidu, Inc. Stock Quote
Baidu, Inc.
BIDU
$118.75 (-0.06%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.